Search results
Results from the WOW.Com Content Network
Iodine-131 (131 I, I-131) is an important radioisotope of iodine discovered by Glenn Seaborg and John Livingood in 1938 at the University of California, Berkeley. [3] It has a radioactive decay half-life of about eight days. It is associated with nuclear energy, medical diagnostic and treatment procedures, and natural gas production.
The beta particles emitted by the radioisotope destroys the associated thyroid tissue with little damage to surrounding tissues (more than 2.0 mm from the tissues absorbing the iodine). Due to similar destruction, 131 I is the iodine radioisotope used in other water-soluble iodine-labeled radiopharmaceuticals (such as MIBG) used therapeutically ...
Sources cite 5,500 to 12,000 curies (200 to 440 TBq) of iodine-131 released, [1] [2] [3] and an even greater amount of xenon-133. The radiation was distributed over populated areas and caused the cessation of intentional radioactive releases at Hanford until 1962, when more experiments commenced.
[1] [2] When the iodine atom is a radioactive isotope (iodine-125 or iodine-131), it is used as an adrenal cortex radiotracer in the diagnosis of patients suspected of having Cushing's syndrome, hyperaldosteronism, [3] pheochromocytoma, and adrenal remnants following total adrenalectomy. [1] [2]
iodine-131: 8.02 693 polonium-206: 8.8 760 thulium-167: 9.25 799 gadolinium-149: 9.28 ... The PDF of this article lists the half-lives of all known radioactives nuclides.
The patient swallows a radioisotope of iodine in the form of capsule or fluid, and the absorption (uptake) of this radiotracer by the thyroid is studied after 4–6 hours and after 24 hours with the aid of a scintillation counter. The dose is typically 0.15–0.37 MBq (4–10 μCi) of 131 I iodide, or 3.7–7.4 MBq (100–200 μCi) of 123 I ...
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
Technetium (99m Tc) sestamibi (commonly sestamibi; USP: technetium Tc 99m sestamibi; trade name Cardiolite) is a pharmaceutical agent used in nuclear medicine imaging.The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands.